Akero Therapeutics Inc. (NASDAQ:AKRO) does about 353.54K shares in volume on a normal day but saw 274371 shares change hands in Tuesday trading. The company now has a market cap of 1.24B USD and an enterprise value of about $1.32B. Its current market price is $36.42, marking a decrease of -4.13% compared to the previous close of $37.99. The 52 week high reached by this stock is $41.16 whilst the lowest price level in 52 weeks is $10.78. The script in recent trading has seen the stock touch a high of $39.10 and a low of $35.95.
Akero Therapeutics Inc. (AKRO) has a 20-day trading average at $33.03 and the current price is -11.52% off the 52-week high compared with 237.85% distance from its 52-week low. The 50-day simple moving average of the closing price is $27.79 and its 200-day simple moving average is $22.70. If we look at the stock’s price movements over the week, volatility stands at 6.33%, which increases to 8.48% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 61.73 to suggest the stock is neutral.
6 analysts observing the Akero Therapeutics Inc. (AKRO) stock have set the 12-month price targets for the company’s shares at between $41.00 and $80.00. The consensus objective for the share price is $57.67, suggesting that the stock has a potential upside of 36.85% over the period. The median price target is 35.54% away from the current levels at $56.50.
FactSet Research has provided data showing that 6 brokerages have issued ratings for the stock. 0 analysts have rated it as a sell, while 0 advise that it is a overweight. 6 analysts have rated it as a buy and 0 have advised that investors hold their positions. The consensus recommendation rating is Buy and Wall Street’s advice is for investors to Strong Buy the stock.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on July 20, 2020 when H.C. Wainwright reiterated the stock to “Buy” and issued a price target of between $45 and $62. H.C. Wainwright reiterated its price target at $33-$45.
The current price level is 11.91%, 32.43%, and 61.00% away from its SMA20, SMA50, and SMA200 respectively, with the AKRO price moving above the 50-day SMA on July 21. Akero Therapeutics Inc. (AKRO) stock is up 3.50% over the week and 36.10% over the past month. Its price is 64.09% year-to-date and 62.73% over the past year.
The stock last released its quarterly earnings report for quarter ended 3/30/2020, with the company’s earnings per share (EPS) of -$0.42 above consensus estimates by $0.19. The company’s next earnings report is expected on 08/17/2020, with forecasts estimating quarterly EPS at -$0.62 and -$2.63 for whole year. AKRO’s earnings per share are forecast to grow by 9.30% this year and -41.10% over next year.
Its 12-month price target is $56.50. To reach the target analysts have set, the stock logically needs to grow 36.85 percent from here. Of course, the average price target is just what the average analysts believe a stock will be worth in the next 52 weeks, and is only one metric. There are analysts with lower targets than the average, including one bearish Wall Street research firm advocating investors to wait for the price to pull back to $41.00, given the recent momentum. And then, on the bullish side of things, one analyst is expecting the stock to peak at $80.00.
Outstanding shares total 28.50M with insiders holding 9.51% of the shares and institutional holders owning 84.23% of the company’s common stock. The company has a return on equity of -36.60%. Price to book ratio is 8.78.
According to a U.S. Securities and Exchange Commission filing, Janus Henderson Global Life Scien has added its position in Akero Therapeutics Inc. (AKRO) to 977,376 shares, mirroring a recent increase by 7.44%. Janus Henderson Global Life Scien added 67684.0 shares of Akero Therapeutics Inc. common stock bringing its total worth to about $24.36 million at the end of recent close, SEC documents show. Janus Henderson Global Life Scien isn’t the only investment manager who changed stakes and is followed by Janus Henderson Capital Funds Plc, which sold off 0.0 shares to end up with 617,430 shares worth $15.39 million. ACAP Strategic Fund raise their holdings by 84.77% in the company over the course of the most recent quarter. It now holds a 1.32% position in Akero Therapeutics Inc. thanks to 0.38 million shares amounting to $9.4 million.